Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Xintela AB is currently managing 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are distributed across 2 distinct examiners and 2 distinct art units, indicating a broader reach within the patent office. This distribution suggests that the company is pursuing multiple technical paths or distinct inventions that have been categorized into different examination groups. Such a spread requires a coordinated management strategy to ensure consistency across the portfolio as it moves through different sectors of the Biotechnology & Pharmaceuticals division.
The busiest examiner for the portfolio is JOHNSON, ALLISON MARIE, who is assigned 1 pending office action. This indicates that the 2 pending office actions are distributed among the 2 distinct examiners involved in the company's current filings. The involvement of 2 distinct art units implies that the subject matter spans different specialized areas, which may lead to varying examination timelines. Practitioners must coordinate strategies across these different units and examiners to ensure consistent prosecution. This multi-examiner environment provides a diverse set of feedback that can help the company refine its overall intellectual property approach while navigating the specific requirements of JOHNSON, ALLISON MARIE.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| JOHNSON, ALLISON MARIE | 1 | 40.9% | +53.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17923124 | Stem Cells for Treatment of Respiratory Disorders | JOHNSON, ALLISON MARIE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17923124 | Stem Cells for Treatment of Respiratory Disorders | JOHNSON, ALLISON MARIE | — |
| Art Unit | Apps |
|---|---|
| 1638 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17923124 | Stem Cells for Treatment of Respiratory Disorders | JOHNSON, ALLISON MARIE | 1638 | §103§112 | Final Rejection | — | Pending | Nov 03, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialXintela AB has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Allison Marie Johnson has the most, with 1 of Xintela AB's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
